Sidekick Health today announced a collaboration on an integrated digital therapeutics solution in conjunction with Eli Lilly (NYSE:LLY).
The collaboration between the companies will mark the first phase of a relationship between Sidekick and Lilly, which starts with a digital therapeutic offering for patients battling breast cancer.
According to a news release, the first phase will consist of the integrated digital therapeutic offering rollout in Germany. Reykjavik, Iceland-based Sidekick said the further expansion of its portfolio of digital therapeutics into the treatment of breast cancer will be tailored to support the needs of patients within Lilly’s oncology treatment programs.
“We are extremely excited to be announcing our collaboration with Lilly,” Sidekick CEO and co-founder Dr. Tryggvi Thorgeirsson said in the release. “Cancer is one of the leading causes of death worldwide and is sadly a disease that will likely affect e…